title: Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009.
abstract: The susceptibility trends for Bacteroides fragilis and related species against various antibiotics were determined using data from 3 years of surveillance (2010-2012) on 779 isolates referred by 7 medical centers. The antibiotic test panel included imipenem, ertapenem, meropenem, ampicillin-sulbactam, piperacillin-tazobactam, cefoxitin, clindamycin, moxifloxacin, tigecycline, linezolid, chloramphenicol and . MICs were determined using the agar dilution CLSI reference method. Carbapenem resistance remained low (range 1.1%-2.5%) and unchanged from 2008 to 9 through 2010-2012. Resistance also remained low to the beta-lactam/beta-lactamase inhibitor combinations (1.1%-4.4%). While resistance to clindamycin and moxifloxacin remained high; rates were lower for B. fragilis in 2010-12 (24% and 19% respectively) compared to the earlier time frame of 2008-9 (29% and 35% respectively for the earlier time frame). There were notable species and resistance associations which have been demonstrated previously. No resistance to metronidazole or chloramphenicol resistance was seen. These data demonstrate the continued variability in resistance among Bacteroides and Parabacteroides species, but do demonstrate that carbapenems and beta-lactam/beta-lactamase inhibitor combinations remain very active throughout the United States.
authors.affiliation: Tufts Medical Center, Box 238, 800 Washington Street, Boston, MA, 02111, USA; Tufts University School of Medicine, Boston, MA, USA. Electronic address: dsnydman@tuftsmedicalcenter.org.
authors.forename: D R
authors.initials: DR
authors.lastname: Snydman
authors.affiliation: Tufts Medical Center, Box 238, 800 Washington Street, Boston, MA, 02111, USA.
authors.forename: N V
authors.initials: NV
authors.lastname: Jacobus
authors.affiliation: Tufts Medical Center, Box 238, 800 Washington Street, Boston, MA, 02111, USA.
authors.forename: L A
authors.initials: LA
authors.lastname: McDermott
authors.affiliation: RM Alden Research Laboratory, Santa Monica, CA, USA.
authors.forename: E J C
authors.initials: EJ
authors.lastname: Goldstein
authors.affiliation: Duke University Medical Center, Durham, NC, USA.
authors.forename: L
authors.initials: L
authors.lastname: Harrell
authors.affiliation: New York Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USA.
authors.forename: S G
authors.initials: SG
authors.lastname: Jenkins
authors.affiliation: University of Michigan Medical Center, Ann Arbor, MI, USA.
authors.forename: D
authors.initials: D
authors.lastname: Newton
authors.affiliation: Mayo Clinic, Rochester, MN, USA.
authors.forename: R
authors.initials: R
authors.lastname: Patel
authors.affiliation: Loyola University, Maywood, IL, USA.
authors.forename: D W
authors.initials: DW
authors.lastname: Hecht
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology*; D001439:Bacteroides / Q000187:drug effects; D001442:Bacteroides Infections / Q000188:drug therapy* / Q000382:microbiology; D001441:Bacteroides fragilis / Q000187:drug effects; D041963:Bacteroidetes / Q000187:drug effects*; D015780:Carbapenems / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D006801:Humans; D008826:Microbial Sensitivity Tests; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D010878:Piperacillin / Q000494:pharmacology; D000077725:Piperacillin, Tazobactam Drug Combination; D014481:United States; D065093:beta-Lactamase Inhibitors / Q000494:pharmacology*
chemical_list: D000890:Anti-Infective Agents; D015780:Carbapenems; D065093:beta-Lactamase Inhibitors; D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D010878:Piperacillin
keywords: Antimicrobial resistance; Bacteroides species; In-vitro susceptibility; Parabacteroides species; Surveillance